

The role of recipient myosteatosi s in graft and patient survival after deceased donor liver transplantation

Zoltan Czigan y¹ , Wiebke Kramp¹, Isabella Lurje^{1,5}, Hannah Miller^{1,6}, Jan Bednarsch¹, Sven Arke Lang¹, Tom Florian Ulmer¹, Philipp Bruners², Pavel Strnad³, Christian Trautwein³, Martin Wolfgang von Websky⁴, Frank Tacke^{3,5}, Ulf Peter Neumann^{1,7} & Georg Lurje^{1,6*} 

¹Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany, ²Institute of Radiology, University Hospital RWTH Aachen, Aachen, Germany, ³Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany, ⁴Department of Surgery, University Hospital Bonn, Bonn, Germany, ⁵Department of Hepatology and Gastroenterology, Campus Charité Mitte|Campus Virchow-Klinikum, Charité—Universitätsmedizin Berlin, Berlin, Germany, ⁶Department of Surgery, Campus Charité Mitte|Campus Virchow-Klinikum, Charité—Universitätsmedizin Berlin, Berlin, Germany, ⁷Department of Surgery, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands

Abstract

Background Myosteatosi s is associated with perioperative outcomes in orthotopic liver transplantation (OLT). Here, we investigated the effects of body composition and myosteatosi s on long-term graft and patient survival following OLT.

Methods Clinical data from 225 consecutive OLT recipients from a prospective database were retrospectively analysed (May 2010 to December 2017). Computed tomography-based lumbar skeletal muscle index (SMI) (muscle mass) and mean skeletal muscle radiation attenuation (SM-RA) (myosteatosi s) were calculated using a segmentation tool (3D Slicer). Patients with low skeletal muscle mass (low SMI) and myosteatosi s (low SM-RA) were identified using predefined and validated cut-off values.

Results The mean donor and recipient age was 55 ± 16 and 54 ± 12 years, respectively. Some 67% of the recipients were male. The probability of graft and patient survival was significantly lower in patients with myosteatosi s compared with patients with higher SM-RA values ($P = 0.011$ and $P = 0.001$, respectively). Low skeletal muscle mass alone was not associated with graft and patient survival ($P = 0.273$ and $P = 0.278$, respectively). Dividing the cohort into quartiles, based on the values of SMI and SM-RA, resulted in significant differences in patient but not in graft survival ($P = 0.011$). Even though multivariable analysis identified low SM-RA as an important prognostic marker (hazard ratio: 2.260, 95% confidence interval: 1.177–4.340, $P = 0.014$), myosteatosi s lost its significance when early mortality (90 days) was excluded from the final multivariable model. Patients with myosteatosi s showed significantly higher all-cause mortality and in particular higher rates of deaths due to respiratory and septic complication ($P = 0.002$, $P = 0.022$, and $P = 0.049$, respectively).

Conclusions Preoperative myosteatosi s may be an important prognostic marker in patients undergoing deceased donor liver transplantation. The prognostic value of myosteatosi s seems to be particularly important in the early post-operative phase. Validation in prospective clinical trials is warranted.

Keywords Liver transplantation; Body composition; Myosteatosi s; Sarcopenia; Graft survival; Patient survival

Received: 1 September 2020; Revised: 28 November 2020; Accepted: 16 December 2020

*Correspondence to: Georg Lurje, Department of Surgery, Campus Charité Mitte|Campus Virchow-Klinikum, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Phone: +49-30-450652339, Fax: +49-30-450552900, Email: georg.lurje@charite.de

Introduction

Pathological variations of body composition (BC) are frequently seen in critical illness and have been associated with

inferior clinical outcomes in a variety of medical conditions.^{1,2} Accordingly, malnutrition and muscle wasting are characteristic for patients with chronic liver disease,^{1,3} and as such, nutritional screening as well as the assessment of BC were

recently implemented in the European Association for the Study of the Liver and American Association for the Study of Liver Diseases practice guidelines on nutrition in chronic liver disease.^{4,5}

Even though numerous methods are used for clinical BC assessment,⁶ the direct quantification of muscle and fat tissue using cross-sectional computed tomography (CT) imaging is considered the gold standard in transplant waiting list candidates and in patients with chronic liver disease.^{1,4,6} While sarcopenia—the pure loss of muscle mass and strength—was linked to clinical outcomes in various diseases,^{3,6–10} the long-term prognostic value of muscle quality (muscle density or myosteatosi) compared with muscle quantity (muscle mass or sarcopenia) remains to be determined.^{1,3,7–9}

Nowadays, an increasing number of extended criteria donor allografts are utilized that were previously considered unsuitable for transplantation.^{11,12} Because of that, a careful selection and matching of donors and recipients are essential to improve allograft utilization and post-orthotopic liver transplantation (OLT) outcomes.¹³ Recent studies by our group and others demonstrated a high prevalence of BC alterations in patients with end-stage liver disease. In particular, myosteatosi was identified as an important prognostic factor in predicting adverse perioperative outcomes in patients undergoing OLT.^{9,10,14–17}

Because myosteatosi seems to be an accurate predictor for clinical outcomes, the goal of the present study was to assess the performance of CT-based recipient BC profiling in predicting long-term graft and patient survival in individuals undergoing deceased donor OLT.

Methods

Patients and ethics

Between May 2010 and December 2017, all consecutive patients undergoing OLT at the University Hospital RWTH Aachen (UH-RWTH), Aachen, Germany, were considered for inclusion. Exclusion criteria were defined as (i) CT scans older than 6 months and/or those not including images from the third lumbar vertebra (L3) level¹⁴ and (ii) living related or split liver transplantation. Patients undergoing re-OLT have been assessed only for the primary transplantation, and consecutive transplantations were included in the follow-up. The study was conducted at the UH-RWTH in accordance with the current version of the Declaration of Helsinki as well as the Declaration of Istanbul and the International Conference on Harmonisation Good Clinical Practice guidelines. The study was approved by the responsible Institutional Review Board of the RWTH Aachen University (EK 047/18). Informed

consent was waived because of the retrospective study design and collection of readily available clinical data.

Segmentation and body composition analysis

All CT scans were performed by using a state-of-the-art multi-slice CT scanner. The technical parameters for CT imaging were described before.¹⁴

Data of the most recent preoperative CT imaging were retrieved from digital storage in the picture archiving and communication system. Body composition analysis was performed as previously described by our group.¹⁴ Briefly, a single cross-sectional CT image at the level of L3 was used, and the segmentation of skeletal muscle and adipose tissue was performed using the 3D Slicer software platform Version 4.1 and BC module (<https://www.slicer.org/>¹⁸) in a semi-automatic fashion. Skeletal muscle area was identified and quantified by using attenuation values of -29 to 150 Hounsfield units (HU). Skeletal muscle index [SMI; the indicator of low skeletal muscle mass (SMM) or structural aspect of sarcopenia] has been calculated by normalizing the measured muscle area to the square height of the patient (cm^2/m^2).¹⁴ Skeletal muscle radiation attenuation (SM-RA) as an indicator of muscle density and myosteatosi has been recorded in HU.¹⁴ Visceral fat was quantified by using the attenuation values -150 to -50 HU. To identify subcutaneous adipose tissue, the attenuation values of -190 to -30 were used (*Figure 1*).¹⁴ All measurements were performed by the same researcher, experienced in complex BC analyses.

Based on the SMI and SM-RA, reduced SMM and myosteatosi were defined using cut-off values determined specifically for patients on OLT waiting list (SMI: female $39 \text{ cm}^2/\text{m}^2$ and male $50 \text{ cm}^2/\text{m}^2$; SM-RA < 41 HU for patients with a body mass index up to $24.9 \text{ kg}/\text{m}^2$ and < 33 HU for patients with a body mass index $\geq 25 \text{ kg}/\text{m}^2$).^{6,14,19} Based on previous literature findings from patient cohorts with terminal liver disease, no adjustment for sex was made for SM-RA.^{6,14}

Perioperative management and data collection

All OLT waiting list indications were discussed and decided within a multidisciplinary liver transplantation board meeting in accordance to the German national and Eurotransplant guidelines (Eurotransplant Manual Version 5.5, Eurotransplant Foundation, Leiden, the Netherlands). Organ allocation followed national and Eurotransplant regulations. The liver transplantation procedure was performed using a standardized approach of total cava replacement as previously described.^{14,20} The standard perioperative care and immunosuppression regimen consisted of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids.^{14,20}




Figure 1 Segmentation of cross-sectional computed tomography images at the level of the third lumbar vertebra. Representative axial images of the preoperative CT scan of a 55-year-old male patient underwent liver transplantation for hepatocellular carcinoma during the study period. (A, B) Skeletal muscle area (red) was determined by using computed tomography attenuation values of -29 to 150 HU. Subcutaneous fat area (light green) was defined as attenuation values of -190 to -30 HU. For visceral fat area (dark green), -150 to -50 HU attenuation values were used. In this patient with considerable structural alterations of the skeletal muscle, panel C shows the amount of intramuscular adipose tissue in dark green (-190 to -50 HU). While normal attenuation muscle has been marked red ($+30$ to 150 HU), myosteatotic, low attenuation muscle was delineated in violet (-29 to 29 HU). Note the large amount of low attenuation muscle (violet colour) in panel C, indicating the presence of low-quality myosteatotic muscle.

Clinical data were obtained from a prospective institutional database and analysed, retrospectively. Various OLT risk scores (Table 1) have been calculated as described before.^{14,23,29,30} Extended criteria donor allografts were defined according to the definitions of the German Medical Chamber.²² To assess post-transplant early allograft dysfunction, the Olthoff criteria were adopted.²⁷

Post-operative morbidity was evaluated for all surgical complications observed during the first 90 days after OLT according to the Clavien–Dindo classification and quantified using the comprehensive complication index.^{26,28} Recipient pre-OLT performance status has been assessed using the Karnofsky performance score (KPS).²⁵ Post-operative transfusions were defined as any blood products given within the first 7 days following OLT. Blood products administered later in the post-operative period were categorized as post-operative complications according to the recommendations of the Clavien–Dindo classification.²⁶ Length of intensive care unit (ICU) stay represents the initial stay after the OLT procedure until the transfer of the patient to our standard care transplantation unit. Hospital stay was defined by the date of admission for OLT and the day of discharge from the UH-RWTH. Readmission to the ICU was included in the total hospital stay. Our transplantation outpatient department as well as the responsible general practitioner and/or hepatologist provided all follow-up data used for the survival analyses in this study.

Study endpoints and statistical analysis

Probability of patient survival at 5 years was chosen as the primary endpoint for the survival analyses. Five year graft survival was used as secondary endpoint.

Categorical data are presented in the form of numbers and percentages. Data derived from continuous variables were presented as mean and standard deviation. Categorical data were compared using the χ^2 test or Fisher's exact test

according to scale and number counts. The associations of graft and patient survival with BC characteristics were assessed using univariate and multivariable Cox proportional hazards regression models. Survival curves were generated by the Kaplan–Meier method and compared with the log-rank test. All P -values <0.05 were considered statistically significant. Statistical analysis has been performed using SPSS Statistics v24 (IBM Corp., Armonk, NY, USA).

Results

Patient and graft characteristics

Out of all 357 consecutive OLTs performed, 225 patients met the predefined inclusion and exclusion criteria.¹⁴ Among 132 excluded patients were recipients of living related ($n = 5$) or split liver allografts ($n = 4$), and cases without sufficient preoperative CT imaging ($n = 123$). Patients' characteristics and perioperative outcome data of the cohort were in part reported previously¹⁴ and are also summarized in Table 1.

The median time between the CT imaging used for segmentation and OLT was 5 weeks (range 0–24). The mean SMI was 57 ± 39 cm²/m² for male patients and 47 ± 11 cm²/m² for female patients. The mean SM-RA was 35 ± 11 HU for male patients and 32 ± 11 HU for female patients, respectively. Figure 2 depicts the distribution of the SMI and SM-RA values within the patient cohort.

Impact of low muscle mass and myosteatosis on long-term graft and patient survival

There were 19 patients (8%) who died within the first 90 days following OLT. A total of 59 patients died over the follow-up period (May 2010 to May 2020; see Table 3). The probability of graft survival at 5 years was significantly worse for patients

Table 1 Donor and recipient characteristics

Characteristics	All patients (n = 225)	Patients without 90 day mortality (n = 206)
Donor age (years)	55 ± 16	55 ± 16
Donor BMI	30 ± 8	30 ± 8
Donor sex ratio (F:M)	108 (48%):117 (52%)	100 (48%):106 (52%)
DRI ^a	1.77 ± 0.35	1.76 ± 0.35
Donor cause of death	CVA 138 (61%) Anoxia 51 (23%) Trauma 25 (11%) Other 11 (5%)	CVA 130 (63%) Anoxia 47 (23%) Trauma 21 (10%) Other 8 (4%)
ECD ^b	154 (68%)	139 (68%)
Recipient age (years)	54 ± 12	54 ± 12
Recipient BMI	27 ± 5	27 ± 5
Recipient sex ratio (F:M)	75 (33%):150 (67%)	66 (32%):140 (68%)
Aetiology of liver disease	ALF 31 (14%) HCC 63 (28%) Alc. cirrhosis 45 (20%) Viral 15 (7%) PSC/PBC 21 (9%) Graft failure 4 (2%) Other 46 (20%)	ALF 29 (14%) HCC 57 (28%) Alc. cirrhosis 40 (19%) Viral 13 (6%) PSC/PBC 20 (10%) Graft failure 3 (2%) Other 44 (21%)
Pre-transplant Child–Pugh score	7 ± 2	7 ± 2
Pre-transplant labMELD	20 ± 11	19 ± 10
BAR score ^c	9 ± 6	8 ± 5
SOFT score ^d	15 ± 10	14 ± 9
Recipient pre-transplant ICU	56 (25%)	45 (22%)
Recipient pre-transplant abdominal surgery	82 (36%)	72 (35%)
Recipient pre-transplant encephalopathy	90 (40%)	82 (40%)
Karnofsky performance score ^e	60 ± 25	62 ± 24
Cold ischaemic time (min)	516 ± 139	511 ± 134
Warm ischaemic time (min)	46 ± 7	46 ± 7
Intraoperative red blood cell transfusions (units)	9 ± 8	9 ± 8
Intraoperative fresh frozen plasma transfusions (units)	18 ± 10	17 ± 10
Post-operative red blood cell transfusions (units) ^f	4 ± 6	3 ± 5
Post-operative fresh frozen plasma transfusions (units) ^f	6 ± 11	5 ± 8
90 day ≥CD3b complications ^g	114 (51%)	95 (46%)
90 day mortality	19 (8%)	Not applicable
Early allograft dysfunction n (%) ^h	60 (27%)	53 (26%)
ICU stay (days)	14 ± 23	12 ± 21
Hospital stay (days)	43 ± 42	42 ± 43
90 day CCI ⁱ	54 ± 33	50 ± 31

ALF, acute liver failure; BAR, balance of risk; BMI, body mass index; CCI, comprehensive complication index; CD, Clavien–Dindo classification; CVA, cerebrovascular accident; DRI, donor risk index; ECD, extended criteria donor allografts; HCC, hepatocellular carcinoma; ICU, intensive care unit; MELD, model for end-stage liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SOFT, survival outcomes following liver transplantation.

Values were given as mean ± standard deviation or n (%).

^aRefers to Feng *et al.*²¹

^bRefers to German Medical Chamber guidelines.²²

^cRefers to Schlegel *et al.*²³

^dRefers to Rana *et al.*²⁴

^eRefers to Kelly *et al.*²⁵

^fRefers to blood products given during the first 7 days after orthotopic liver transplantation

^gRefers to Clavien *et al.*²⁶

^hRefers to Olthoff *et al.*²⁷

ⁱRefers to Slankamenac *et al.*²⁸

with myosteatorsis compared with patients with higher muscle density (65% vs. 81%; $P = 0.011$, *Figure 3*). When patients were divided into quartiles based on the SM-RA values, no significant difference was found in terms of graft survival (SM-RA Q4 70% vs. Q3 66% vs. Q2 72% vs. Q1 88%; $P = 0.083$, *Figure 3*).

Similar to the graft survival rates, the probability of patient survival at 5 years was significantly worse for patients with myosteatorsis compared with patients above the defined cut-offs of SM-RA (65% vs. 85%; $P = 0.001$,

Figure 4). When the SM-RA quartiles were considered, there was also a significant difference in patient survival (SM-RA Q4 71% vs. Q3 66% vs. Q2 80% vs. Q1 91%; $P = 0.011$, *Figure 4*).

Alterations of muscle mass alone had no significant effects on graft and patient survival, neither as a single cut-off for low SMM nor as SMI quartiles (*Figures 3 and 4*). Probability of graft and patient survival for individuals with low SMM was 67% and 70% vs. 78% and 80% for individuals without low SMM ($P = 0.273$ and $P = 0.278$) (*Figures 3 and 4*).




Figure 2 Distribution of skeletal muscle index (SMI) and skeletal muscle radiation attenuation (SM-RA) values within the patient cohort. (A) Quartile-based distribution of lumbar 3 SMI. (B) Quartile-based distribution of lumbar 3 SM-RA.




Figure 3 Probability of graft survival stratified by body composition. (A) Normal skeletal muscle mass (SMM) 78% vs. low SMM 67%. (B) Skeletal muscle index (SMI) Q4 73% vs. Q3 75% vs. Q2 68% vs. Q1 80%. (C) No myosteatosi 81% vs. myosteatosi 65%. (D) Skeletal muscle radiation attenuation (SM-RA) Q4 70% vs. Q3 66% vs. Q2 72% vs. Q1 88%.

Because most of the difference in survival occurred during the early post-OLT phase (Figures 3 and 4), emphasizing the significant effects of myosteatosi on perioperative outcomes,¹⁴ secondary survival analyses with exclusion of patients who have died within the first 90 days after OLT ($n = 19$) were carried out (Figure 5). Interestingly, myosteatosi lost its prognostic value for graft and patient survival ($P = 0.011$ vs. $P = 0.477$ and $P = 0.001$ vs. $P = 0.092$, respectively; see Figures 3–5). The significant difference of

the log-rank test between the SM-RA quartiles for patient survival was also lost when individuals with early mortality were excluded from the analysis ($P = 0.011$ vs. $P = 0.303$, Figures 4 and 5).

We next performed univariable and multivariable Cox regression analyses to identify independent risk factors for graft loss and overall mortality. Although our univariable Cox proportional hazards regression model showed a relevant association of recipient pre-transplant ICU stay [odds




Figure 4 Probability of patient survival stratified by body composition. (A) Normal skeletal muscle mass (SMM) 80% vs. low SMM 70%. (B) Skeletal muscle index (SMI) Q4 73% vs. Q3 80% vs. Q2 73% vs. Q1 80%. (C) No myosteatosi 85% vs. myosteatosi 65%. (D) Skeletal muscle radiation attenuation (SM-RA) Q4 71% vs. Q3 66% vs. Q2 80% vs. Q1 91%.

ratio (OR) 2.213, 95% confidence interval (CI) 1.256–3.899, $P = 0.006$], KPS (OR 1.773, 95% CI 1.018–3.088, $P = 0.043$), intraoperative transfusion of red blood cell units (OR 2.252, 95% CI 1.232–4.116, $P = 0.008$), and the presence of myosteatosi (OR 2.025, 95% CI 1.154–3.553, $P = 0.014$) with graft survival, none of these factors remained significant in the final multivariable model (Supporting Information, Tables S1 and 2).

The multivariable analysis has identified myosteatosi as an independent factor associated with impaired patient survival (OR 2.260, 95% CI 1.177–4.340, $P = 0.014$, Tables S1 and 2). In contrast, although labMELD (OR 1.909, 95% CI 1.060–3.439, $P = 0.031$), pre-transplant ICU stay (OR 2.798, 95% CI 1.553–4.041, $P = 0.001$), KPS (OR 2.399, 95% CI 1.327–4.336, $P = 0.004$), and intraoperative transfusion of red blood cell units (OR 2.102, 95% CI 1.109–3.987, $P = 0.023$) showed significant hazard ratios (HRs) in the univariable analysis, they lost their significance in the multivariable model (Tables S1 and 2).

In line with the observations made in the Kaplan–Meier analysis and log-rank tests, the significant association of myosteatosi with a decreased graft and patient survival was lost already in the univariable analysis when early mortality (90 day mortality, $n = 19$) was excluded from the analysis resulting in an HR of 1.290 (0.636–2.617) and a P -value = 0.481 for graft survival and an HR of 1.914 (0.885–4.141) and a P -value = 0.099 for patient survival (Tables S1 and 2).

Furthermore, patients with myosteatosi showed significantly higher all-cause mortality (37% vs. 18%: $P = 0.002$) and a higher incidence of deaths due to respiratory and septic complications (8% vs. 2%: $P = 0.022$ and 16% vs. 8%: $P = 0.049$, respectively; see Table 3).

Discussion

This study explores the association of myosteatosi with long-term post-OLT graft and patient survival. While there was a high incidence of pathological BC alterations in our cohort with more than 40% of our patients suffering from myosteatosi and 37% presenting with low SMM, we here show a limited long-term prognostic role of myosteatosi and low SMM in deceased donor OLT. Interestingly, based on our data, the prognostic value of myosteatosi seems to be accentuated in the early post-operative phase, as BC loses its prognostic value on long-term outcomes when patients with early mortality are excluded.

Because the gap between allograft supply and demand continues to increase, the optimal risk stratification and utilization of the available donor pool are based not only on conventional risk factors but also on nutritional donor–recipient characteristics.^{13,14,31} While a handful of reports have suggested a potential role of myosteatosi in clinical outcome




Figure 5 Probability of graft and patient survival stratified by myosteator after excluding 90 day mortality. To show the long-term effects of myosteator, subgroup survival analyses were repeated, and patients who died within 90 days of transplantation ($n = 19$) were excluded. (A) Graft survival by no myosteator 83% vs. myosteator 77%. (B) Graft survival by skeletal muscle radiation attenuation (SM-RA) Q4 81% vs. Q3 78% vs. Q2 77% vs. Q1 87%. (C) Patient survival by no myosteator 88% vs. myosteator 77%. (D) Patient survival by SM-RA Q4 81% vs. Q3 84% vs. Q2 82% vs. Q1 88%.

Table 2 Multivariable Cox regression analysis of prognostic factors for graft and patient survival

	Graft survival—multivariable analysis		Patient survival—multivariable analysis	
	Hazard ratio (95% confidence interval)	P-value	Hazard ratio (95% confidence interval)	P-value
Pre-transplant labMELD ≥ 25	n.a.	n.a.	0.767 (0.318–1.850)	0.555
Recipient pre-transplant ICU yes	1.969 (0.780–4.967)	0.151	2.169 (0.854–5.510)	0.104
Karnofsky performance score <60	0.801 (0.317–2.020)	0.638	1.197 (0.339–3.597)	0.748
Intraoperative RBC units ≥ 15	1.735 (0.908–3.316)	0.095	1.446 (0.732–2.855)	0.288
Myosteator (SM-RA) yes	1.716 (0.937–3.143)	0.080*	2.260 (1.177–4.340)	0.014 [#]

ICU, intensive care unit; MELD, model for end-stage liver disease; RBC, red blood cell; SM-RA, skeletal muscle radiation attenuation.

Results from the Cox proportional hazards regression model were given as hazard ratios (HR) with 95% confidence intervals. Factors showing significant results in the univariable analysis (see Table S1) were included into the multivariable logistic regression model. Only significant results are shown. To avoid a multicollinearity effect, certain variables were not included into the Cox regression model.

*When removing patients with perioperative mortality (90 day mortality, $n = 19$), myosteator loses its significant effect on graft survival (hazard ratio: 1.290, 95% confidence interval: 0.636–2.617, $P = 0.481$ in univariable analysis).

[#]When removing patients with perioperative mortality, myosteator loses its significant effect on patient survival (hazard ratio: 1.914, 95% confidence interval: 0.885–4.141, $P = 0.099$ in univariable analysis).

following OLT, the majority of previous studies focused on sarcopenia and on Asian cohorts of living donor liver transplantation (LDLT).^{1,6,9,14,32,33} In addition, recent data from our group and others suggest that myosteator, as characterized by the presence of intermyocellular and intramyocellular fat depositions, may result in dysregulated pathophysiological responses and consequential inferior clinical outcomes even in patients with normal or slightly reduced muscle

mass.^{6,14} In a recent report by Hamaguchi *et al.*, the authors investigated CT-based BC in a single-centre Japanese cohort of 657 living liver donors and identified SMI and intramuscular adipose tissue content (IMAC) as independent predictors of post-transplant recipient survival.³³ A further study by the same group evaluated IMAC and psoas muscle mass index in 200 adult recipients undergoing LDLT and demonstrated a significant association of recipient mortality with

Table 3 Cause of death for all patients died until the time point of last follow-up

Cause of death	All patients (n = 225)	Myosteato sis (n = 98)	No myosteato sis (n = 127)	P- value
All	59 (26)	36 (37)	23 (18)	0.002
Primary non- function	2 (1)	2 (2)	0 (0)	0.189
Gastrointestinal	1 (<1)	1 (1)	0 (0)	0.436
Respiratory	10 (4)	8 (8)	2 (2)	0.022
Recurrent liver disease	7 (3)	3 (3)	4 (3)	0.970
Septic	26 (12)	16 (16)	10 (8)	0.049
Malignancy	6 (3)	2 (2)	4 (3)	0.699
Other	7 (3)	4 (4)	3 (2)	0.408

Total follow-up period reported: May 2010 to May 2020.

high IMAC and low psoas muscle mass index.³² Furthermore, Bhanji *et al.* reported a correlation of myosteatosi s with hepatic encephalopathy and waiting list mortality in a large cohort of 675 cirrhotic patients.³ Although, myosteatosi s was previously linked to inferior waiting list survival in end-stage liver disease and in patients undergoing LDLT, its specific effects on graft and patient survival in patients undergoing deceased donor OLT remained to be determined.^{1,3,9,14,34}

Recently, our group investigated the role of myosteatosi s and low SMM in early perioperative outcomes.¹⁴ Patients with myosteatosi s experienced a higher number and more severe surgical complications over the first 3 months following OLT. Also, increased rates of early allograft dysfunction, higher comprehensive complication index scores, longer ICU and hospital stays, higher procedural costs, and an increased need for intraoperative blood transfusions were seen in patients with myosteatosi s.¹⁴ Of note, low SMM alone was not associated with any of the previously perioperative outcome parameters. To further explore this observation, we investigated the prognostic role of muscle quality (myosteatosi s) and low SMM in post-OLT graft and patient survival. Patients were divided into low and normal SM-RA and SMI cohorts and were also stratified into SM-RA and SMI quartiles (*Figures 2–5*). For this, we used validated cut-off values from large cohorts of patients with chronic liver disease, adopting recent recommendations of the North American expert group on fitness, life enhancement, and exercise in liver transplantation.^{6,8,19,35}

In the present study, the probability of graft and patient survival at 5 years was significantly worse in the presence of myosteatosi s. Our quartile-based analysis of patient survival also showed significant differences between the various SM-RA quartiles. Patients belonging to the first SM-RA quartile (thus having the highest muscle density) demonstrated an excellent 91% patient survival compared with 66% and 71% in Q3 and Q4, respectively ($P = 0.011$).

Subsequently, BC parameters were fitted into a Cox proportional hazards regression model to further assess the association of low SMM and myosteatosi s with graft and

patient survival in our cohort. Here, we identified the presence of myosteatosi s as an independent predictor of inferior 5 year patient survival in the final multivariable model. Interestingly, the significant effect of myosteatosi s on graft and patient survival was lost in our secondary univariable and multivariable analyses where patients who died within the first 90 days after OLT were excluded. Low SMM did not show any significant hazard ratios in the analysis for graft and patient survival.

Next, cause of mortality over the observation period was analysed in detail to further explore the role myosteatosi s in mortality. Patients with myosteatosi s showed not only significantly higher all-cause mortality, but also death due to respiratory and septic complication were more frequent in the myosteatosi s subcohort. This is in line with previous findings, showing that structural alteration of the skeletal muscle compartment and muscle wasting are associated with infectious and respiratory complications, not only in liver disease and OLT but also in various oncological entities.^{1,16,36,37}

Although myosteatosi s can occur when lipid intake simply exceeds the disposal capacity of the human body,^{7,14,38} pathological fat deposition was also confirmed in non-obese or even in underweight patients,^{14,39} highlighting that mechanisms other than exogenous lipid intake (e.g. liver–muscle crosstalk and alterations of lipoprotein metabolism in liver disease) may play an important role in the development of myosteatosi s in patients with chronic liver disease.^{6,7,14} These observations support previous findings on the potent short-term effects of myosteatosi s and low muscle density.^{6,14} While inflammatory responses play a pivotal role in early ischaemia–reperfusion injury of the liver allograft (ischaemic complications and rejection),⁴⁰ a pro-inflammatory tissue micro-environment as it is the case in the presence of myosteatosi s likely also impacts early graft and patient survival following OLT.

The findings of this study should be interpreted in the light of potential limitations. First, due to the inherent uncontrolled, retrospective, and single-centre nature of our analysis, no preoperative functional assessment of fitness, muscle strength, and nutritional status was possible.^{9,14} Second, despite our observation and important conclusion on the effects of myosteatosi s on clinical outcome (predominantly short-term), there was still a non-significant difference in the Kaplan–Meier curves for graft and patient survival even after exclusion of early mortality (*Figure 4*). It is therefore reasonable to assume that our analysis may have also been limited by the sample size and a relatively heterogeneous study population.

Notwithstanding the aforementioned limitations, we identified recipient myosteatosi s as an important prognostic marker for clinical outcomes following deceased donor OLT. The prognostic value of myosteatosi s seems to be particularly important in the early post-OLT phase. This observation is not

only important for our understanding on how inter-individual alterations of BC influence clinical outcomes in these patients, but it may also represent an important therapeutic target for interventions during the perioperative phase. Validation in prospective interventional clinical trials is warranted.

Funding

This research project was in part supported by the START Program (136/17 to G.L. and 23/19 to Z.C.) and the Clinician Scientist Program (to Z.C.) of the Faculty of Medicine, RWTH Aachen University and by the Excellence Initiative of the German federal and state governments (G:(DE-82) ZUK2-SF-OPSF443 to G.L.) without involvement of the funders in study design, data collection, data analysis, manuscript preparation, or decision to publish.

Author contributions

The study was designed by the initiating study team (Z.C., G.L., and U.P.N.). Data collection and analysis were performed by Z.C., W.K., I.L., J.B., H.M., P.S., S.A.L., T.F.U., P.B., U.P.N., and G.L. Manuscript was drafted by Z.C., G.L., M.W.v.W., and W.K. Further authors (W.K., I.L., H.M., J.B., S.A.L.,

T.F.U., P.B., P.S., C.T., M.W.v.W., F.T., U.P.N., and G.L.) have substantially contributed to the final version of the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgement

The authors of this paper certify that they comply with the ethical guidelines for authorship and publishing of the *Journal of Cachexia, Sarcopenia and Muscle*.⁴¹ Open access funding enabled and organized by Projekt DEAL.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Univariable Cox regression analysis for graft- and patient survival

Conflict of interest

None declared.

References

- Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2014;**20**:640–648.
- Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2013;**19**:1396–1402.
- Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. *Hepatal Int* 2018;**12**:377–386.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatal* 2019;**70**:172–193.
- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology (Baltimore, Md)* 2018;**67**:328–357.
- Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis—the confluence of 2 prognostic titans. *Liver Int Off J Int Assoc Study Liver* 2018;**38**:1706–1717.
- Nachit M, Leclercq IA. Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms! *Clin Sci (London, England: 1979)* 2019;**133**:465–481.
- Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. *J Cachexia Sarcopenia Muscle* 2016;**7**:126–135.
- Bhanji RA, Takahashi N, Moynagh MR, Narayanan P, Angirekula M, Mara KC, et al. The evolution and impact of sarcopenia pre- and post-liver transplantation. *Aliment Pharmacol Ther* 2019;**49**:807–813.
- Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. *J Am Coll Surg* 2010;**211**:271–278.
- Czigany Z, Lurje I, Schmelzle M, Schoning W, Ollinger R, Raschzok N, et al. Ischemia-reperfusion injury in marginal liver grafts and the role of hypothermic machine perfusion: molecular mechanisms and clinical implications. *J Clin Med* 2020;**9**:846.
- Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, et al. Treatment strategies for hepatocellular carcinoma—a multidisciplinary approach. *Int J Mol Sci* 2019;**20**:1465.
- Boecker J, Czigany Z, Bednarsch J, Amygdalos I, Meister F, Santana DAM, et al. Potential value and limitations of different clinical scoring systems in the assessment of short- and long-term outcome following orthotopic liver transplantation. *PLoS one* 2019;**14**:e0214221.
- Czigany Z, Kramp W, Bednarsch J, van der Kroft G, Boecker J, Strnad P, et al. Myosteatosis to predict inferior perioperative outcome in patients undergoing

- orthotopic liver transplantation. *Am J Trans Off J Am Soc Trans Am Soc Trans Surgeons* 2020;**20**:493–503.
15. Lodewick TM, Roeth AA, Olde Damink SW, Alizai PH, van Dam RM, Gassler N, et al. Sarcopenia, obesity and sarcopenic obesity: effects on liver function and volume in patients scheduled for major liver resection. *J Cachexia Sarcopenia Muscle* 2015;**6**:155–163.
 16. van der Kroft G, van Dijk DPJ, Rensen SS, Van Tiel FH, de Greef B, West M, et al. Low thoracic muscle radiation attenuation is associated with postoperative pneumonia following partial hepatectomy for colorectal metastasis. *HPB (Oxford)* 2020;**22**:1011–1019.
 17. Shenvi SD, Taber DJ, Hardie AD, Botstein JO, McGillicuddy JW. Assessment of magnetic resonance imaging derived fat fraction as a sensitive and reliable predictor of myosteatosis in liver transplant recipients. *HPB (Oxford)* 2020;**22**:102–108.
 18. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. *Magn Reson Imaging* 2012;**30**:1323–1341.
 19. Ebadi M, Tandon P, Moctezuma-Velazquez C, Ghosh S, Baracos VE, Mazurak VC, et al. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. *J Hepatol* 2018;**69**:608–616.
 20. Kienlein S, Schoening W, Andert A, Kroy D, Neumann UP, Schmeding M. Biliary complications in liver transplantation: impact of anastomotic technique and ischemic time on short- and long-term outcome. *World J Transplant* 2015;**5**:300–309.
 21. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DeRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg* 2006;**6**:783–790.
 22. Czigany Z, Schoning W, Ulmer TF, Bednarsch J, Amygdalos I, Cramer T, et al. Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD). *BMJ Open* 2017;**7**:e017558.
 23. Schlegel A, Linecker M, Kron P, Gyori G, De Oliveira ML, Mullhaupt B, et al. Risk assessment in high- and low-MELD liver transplantation. *Am J Trans Off J Am Soc Trans Am Soc Trans Surgeons* 2017;**17**:1050–1063.
 24. Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg* 2008;**8**:2537–2546.
 25. Kelly DM, Bennett R, Brown N, McCoy J, Boerner D, Yu C, et al. Predicting the discharge status after liver transplantation at a single center: a new approach for a new era. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2012;**18**:796–802.
 26. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009;**250**:187–196.
 27. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2010;**16**:943–949.
 28. Slankamenac K, Graf R, Barkun J, Puhani MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. *Ann Surg* 2013;**258**:1–7.
 29. Braat AE, Blok JJ, Putter H, Adam R, Burroughs AK, Rahmel AO, et al. The Eurotransplant donor risk index in liver transplantation: ET-DRI. *Am J Trans Off J Am Soc Trans Am Soc Trans Surgeons* 2012;**12**:2789–2796.
 30. Schoening W, Helbig M, Buescher N, Andreou A, Schmitz V, Bahra M, et al. Eurotransplant donor-risk-index and recipient factors: influence on long-term outcome after liver transplantation—a large single-center experience. *Clin Transplant* 2016;**30**:508–517.
 31. Amygdalos I, Czigany Z, Bednarsch J, Boecker J, Santana DAM, Meister FA, et al. Low postoperative platelet counts are associated with major morbidity and inferior survival in adult recipients of orthotopic liver transplantation. *J Gastrointest Surg* 2020;**24**:1996–2007.
 32. Hamaguchi Y, Kaido T, Okumura S, Fujimoto Y, Ogawa K, Mori A, et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2014;**20**:1413–1419.
 33. Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yao S, et al. Proposal for new selection criteria considering pre-transplant muscularity and visceral adiposity in living donor liver transplantation. *J Cachexia Sarcopenia Muscle* 2018;**9**:246–254.
 34. Thandassery RB, Montano-Loza AJ. Role of nutrition and muscle in cirrhosis. *Curr Treat Options Gastroenterol* 2016;**14**:257–273.
 35. Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2017;**23**:625–633.
 36. Ooi PH, Hager A, Mazurak VC, Dajani K, Bhargava R, Gilmour SM, et al. Sarcopenia in chronic liver disease: impact on outcomes. *Liver Transplant Off Publication Am Assoc Study Liver Dis Int Liver Transplant Soc* 2019;**25**:1422–1438.
 37. Malietz G, Johns N, Al-Hassi HO, Knight SC, Kennedy RH, Fearon KC, et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. *Ann Surg* 2016;**263**:320–325.
 38. Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. *J Cachexia Sarcopenia Muscle* 2011;**2**:111–117.
 39. Hausman GJ, Basu U, Du M, Fernyhough-Culver M, Dodson MV. Intermuscular and intramuscular adipose tissues: bad vs. good adipose tissues. *Adipocyte* 2014;**3**:242–255.
 40. Czigany Z, Lurje I, Tolba RH, Neumann UP, Tacke F, Lurje G. Machine perfusion for liver transplantation in the era of marginal organs—new kids on the block. *Liver Int Off J Int Assoc Study Liver* 2019;**39**:228–249.
 41. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. *J Cachexia Sarcopenia Muscle* 2019;**10**:1143–1145.